Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.

Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB.

Dig Dis Sci. 2010 May;55(5):1396-405. doi: 10.1007/s10620-009-0839-8. Epub 2009 Jun 9.

PMID:
19507029
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Minor DR, Chin K, Kashani-Sabet M.

Cancer Biother Radiopharm. 2009 Jun;24(3):321-5. doi: 10.1089/cbr.2008.0607.

PMID:
19538054
[PubMed - indexed for MEDLINE]
3.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
[PubMed - indexed for MEDLINE]
4.

Ipilimumab-induced acute severe colitis treated by infliximab.

Pagès C, Gornet JM, Monsel G, Allez M, Bertheau P, Bagot M, Lebbé C, Viguier M.

Melanoma Res. 2013 Jun;23(3):227-30. doi: 10.1097/CMR.0b013e32835fb524.

PMID:
23458760
[PubMed - indexed for MEDLINE]
5.

Ipilimumab-induced perforating colitis.

Mitchell KA, Kluger H, Sznol M, Hartman DJ.

J Clin Gastroenterol. 2013 Oct;47(9):781-5. doi: 10.1097/MCG.0b013e31828f1d51.

PMID:
23632354
[PubMed - indexed for MEDLINE]
6.

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL.

Cancer Immun. 2010 Nov 24;10:11.

PMID:
21090563
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.

J Clin Oncol. 2006 May 20;24(15):2283-9.

PMID:
16710025
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA.

J Immunother. 2007 Nov-Dec;30(8):825-30.

PMID:
18049334
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

Johnston RL, Lutzky J, Chodhry A, Barkin JS.

Dig Dis Sci. 2009 Nov;54(11):2538-40. doi: 10.1007/s10620-008-0641-z. Epub 2008 Dec 23.

PMID:
19104936
[PubMed - indexed for MEDLINE]
10.

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP.

Clin Cancer Res. 2007 Mar 15;13(6):1810-5.

PMID:
17363537
[PubMed - indexed for MEDLINE]
Free Article
11.

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D.

J Immunother. 2012 Jan;35(1):89-97. doi: 10.1097/CJI.0b013e31823aa41c.

PMID:
22130166
[PubMed - indexed for MEDLINE]
12.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D.

J Transl Med. 2011 Nov 28;9:204. doi: 10.1186/1479-5876-9-204.

PMID:
22123319
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211
[PubMed - indexed for MEDLINE]
14.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
[PubMed - indexed for MEDLINE]
15.

A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.

Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ.

J Immunother. 2013 Jan;36(1):77-8. doi: 10.1097/CJI.0b013e31827807dd.

PMID:
23211620
[PubMed - indexed for MEDLINE]
16.

Ipilimumab.

[No authors listed]

Drugs R D. 2010;10(2):97-110. doi: 10.2165/11584510-000000000-00000. Review.

PMID:
20698719
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

Lens M, Ferrucci PF, Testori A.

Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):105-13. Review.

PMID:
18537753
[PubMed - indexed for MEDLINE]
18.

Ipilimumab-induced colitis on FDG PET/CT.

Lyall A, Vargas HA, Carvajal RD, Ulaner G.

Clin Nucl Med. 2012 Jun;37(6):629-30. doi: 10.1097/RLU.0b013e318248549a.

PMID:
22614208
[PubMed - indexed for MEDLINE]
19.

Ipilimumab: a promising immunotherapy for melanoma.

Thumar JR, Kluger HM.

Oncology (Williston Park). 2010 Dec;24(14):1280-8. Review.

PMID:
21294471
[PubMed - indexed for MEDLINE]
Free Article
20.

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.

Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.

PMID:
22326924
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk